Resverlogix Corp. (RVXCF)

[noretreat]

Strong. "Current therapies fail to counter progressive systemic inflammation, endothelial dysfunction, vascular calcification, fibrosis, and atherosclerosis in patients with CKD.

The plasma proteome study reported here demonstrated that apabetalone might oppose many of these pathogenic pathways in patients with CKD (and its accompanying comorbidities) by rapidly downregulating plasma markers associated with these dysfunctions. Considering its favorable pharmacokinetic properties in CKD patients and a well-established safety profile, apabetalone is a potential therapeutic agent capable of modulating molecular pathways associated with risk factors that drive CKD progression and its cardiovascular complications."